Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

13.12% of the stock is owned by institutional investors. Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The ...

Regenerative Medicine Market Growth BURLINGAME, CA, UNITED STATES, February 14, 2025 /EINPresswire / --The global Regenerative Medicin ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

As the first first Novartis viral vector production facility in Europe, it significantly expands Novartis' research and ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

Fintel reports that on February 13, 2025, UBS downgraded their outlook for Novartis AG - Depositary Receipt () (NYSE:NVS) ...

Roche Holding AG’s US unit removed diversity and inclusion targets from its website, the latest in a series of publicly traded companies to bow to US President Donald Trump’s push against equal ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) yesterday and set a price target of ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...